Tag archive of Inclusing

Iclusig (ponatinib)

Ponatinib (Iclusig, AP24534) was recently FDA approved for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). It was approved based on the inital results of The PACE (Ponatinb Ph+ ALL and CML Evaluation) trial. B ecasue it not only attacks the CML mutation, BCR-ABL (including the T315I that other drugs doen affect it is an attarctive candidate for personalized use in conditions

Read more